• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    4/29/25 7:32:59 AM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email
    8-K
    false0000730272REPLIGEN CORP00007302722025-04-292025-04-29

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 29, 2025

     

     

    REPLIGEN CORPORATION

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-14656

    04-2729386

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    41 Seyon Street

     

    Waltham, Massachusetts

     

    02453

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (781) 250-0111

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.01 per share

     

    RGEN

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On April 29, 2025, Repligen Corporation announced its financial results for the first quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

     

     

    99.1

     

    Press Release by Repligen Corporation, dated April 29, 2025

     

     

    104

     

    Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    REPLIGEN CORPORATION

     

     

     

     

    Date:

    April 29, 2025

    By:

    /s/ Olivier Loeillot

     

     

     

    Olivier Loeillot

     

     

     

    President and Chief Executive Officer

     

     


    Get the next $RGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$155.00In-line
    Evercore ISI
    2/10/2025$200.00Buy
    TD Cowen
    12/17/2024$165.00Hold
    Canaccord Genuity
    11/14/2024Peer Perform
    Wolfe Research
    8/28/2024$180.00Overweight
    Wells Fargo
    6/26/2024$180.00 → $155.00Hold → Buy
    Deutsche Bank
    6/18/2024Neutral
    Guggenheim
    More analyst ratings